Sugi Predict

Sugi Predict / Compounds / SCHEMBL502040

SCHEMBL502040

SCHEMBL502040

NC(Cc1ccc2ccccc2n1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.53
▸ ALPI P09923 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ XIAP P98170 1/20 0.51
▸ SLC7A5 Q01650 1/20 0.51
▸ GPBAR1 Q8TDU6 2/20 0.47
▸ MGAM O43451 1/20 0.46
▸ CYSLTR1 Q9Y271 2/20 0.45
▸ CYSLTR2 Q9NS75 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430134 1.00 CYP1A2 (0.53) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL839033 1.00 CYP1A2 (0.53) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL502039 1.00 CYP1A2 (0.53) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL10079017 0.86 CYP1A2 (0.55) CYP1A2GPBAR1MGAMCYSLTR1CYSLTR2
SCHEMBL6496060 0.82 CYP1A2 (0.51) CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1
SCHEMBL27484851 0.82 CYP1A2 (0.51) CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1
SCHEMBL25272832 0.81 CYP1A2 (0.47) CYP1A2GPBAR1MGAMALDH1A1
Hydrochloric Acid SCHEMBL6496049 0.81 CYP1A2 (0.50) CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1
SCHEMBL25272833 0.81 CYP1A2 (0.47) CYP1A2GPBAR1MGAMALDH1A1
Hydrochloric Acid SCHEMBL6496063 0.81 CYP1A2 (0.50) CYP1A2GPBAR1CYSLTR1CYSLTR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720086-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 — — EP claimed
EP-4720087-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 — — EP claimed
US-20250353814-A1 NON-PEPTIDIC CELL-PENETRATING MOTIFS OHIO STATE INNOVATION FOUNDATION (US) 2025-11-20 — — US claimed
US-12404236-B2 Non-peptidic cell-penetrating motifs OHIO STATE INNOVATION FOUNDATION (US) 2025-09-02 — — US claimed
US-12329799-B2 Peptidyl inhibitors of calcineurin-NFAT interaction OHIO STATE INNOVATION FOUNDATION (US) 2025-06-17 — — US claimed
WO-2025094171-A1 SUPERHYDROPHOBIC COATING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2025-05-08 — — WO claimed
WO-2024246268-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2024-12-05 — — WO claimed
WO-2024246269-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2024-12-05 — — WO claimed
EP-4401555-A1 ANTIMICROBIAL PEPTIDES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2024-07-24 — — EP claimed
US-20240197896-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY FELDAN BIO INC. (CA) 2024-06-20 — — US claimed
EP-3374520-A1 BIOSENSORS Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2018-09-19 — — EP claimed
CN-108026162-A Cystine knot scaffold platform 豪夫迈·罗氏有限公司 2018-05-11 — — CN claimed
WO-2017081684-A1 BIOSENSORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-05-18 — — WO claimed
US-9631100-B2 Antifouling materials YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-04-25 — — US claimed
US-20150368480-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2015-12-24 — — US claimed
EP-2951195-A1 ANTIFOULING MATERIALS Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) 2015-12-09 — — EP claimed
WO-2014118779-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-08-07 — — WO claimed
WO-2013004716-A1 PEPTIDE BEADS UNIVERSITÄT BASEL (CH) 2013-01-10 — — WO claimed
WO-2006056009-A1 PEPTIDES HAVING ADHESIVE PROPERTIES FOR USE IN SOLID PHASE ASSAY AND CHEMICAL POLYMER SYNTHESIS REGIMES. HEPGENICS PTY LTD (AU) 2006-06-01 — — WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404236-B2 Non-peptidic cell-penetrating motifs TIMM50, TIMM10, PITRM1 CYP1A2 4766/4885ALPI 4656/4885PKM 1287/4885
US-20250353814-A1 NON-PEPTIDIC CELL-PENETRATING MOTIFS TIMM50, TIMM10, PITRM1 CYP1A2 4766/4885ALPI 4656/4885PKM 1287/4885
US-20240197896-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY SCAMP2, SLC7A1, NUMA1 CYP1A2 4872/4885ALPI 3420/4885PKM 901/4885
US-12329799-B2 Peptidyl inhibitors of calcineurin-NFAT interaction CHP1, NFATC1, PPP3R1 CYP1A2 4838/4885ALPI 4341/4885PKM 3842/4885
US-20150368480-A1 ANTIFOULING MATERIALS PFAS, FLNB, FLNA CYP1A2 1080/4885ALPI 4730/4885PKM 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.